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Background: Cyclooxygenase-2(COX-2) promotes carcinogenesis, tumor proliferation, angiogenesis, prevention of
apoptosis, and immunosuppression. Meanwhile, COX-2 over-expression has been associated with tumor behavior
and prognosis in several cancers. This study investigated the antitumor effects of the selective COX-2 inhibitor,
Celecoxib, on breast cancer in vitro and in vivo.
Methods: Human breast cancer MCF-7 and MDA-MB-231 cells were cultured with different concentration (10, 20,
40 μmol/L) of celecoxib after 0-96 hours in vitro. MTT assay was used to determine the growth inhibition of breast
cancer cells in vitro. The expression of COX-2 on mRNA was measured by real-time quantitive PCR analysis. Flow
cytometry was performed to analyze the cell cycle of MCF-7 cells. Levels of PGE2 were measured by ELISA method.
The in vivo therapeutic effects of celecoxib were determined using rat breast cancer chemically induced by
7,12-dimethylben anthracene (DMBA).
Results: The inhibition of proliferation of both MCF-7 and MDA-MB-231 cells in vitro by celecoxib was observerd in
time and dose dependent manner. Celecoxib effectively down-regulated the expression of COX-2. The cell cycle
was arrested at G0/G1, and rate of cells in S phase was obviously decreased. Levels of PGE2 were inhibited by
Celecoxib. The tumor incidence rate of the celecoxib group was lower than that of the control group. In addition,
the tumor latency period of the celecoxib group was longer than that of the control group.
Conclusions: Celecoxib inhibited the proliferation of breast cancer cell lines in vitro, and prevented the occurrence
of rat breast cancer chemically induced by DMBA. Therefore, celecoxib exhibits an antitumor activity and seems to
be effective in anti-tumor therapy.
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Cyclooxygenases(COX) exists in two isoforms, namely,
COX-1 and COX-2. They are rate-limiting enzymes in
the formation of prostaglandins from arachidonic acid.
COX-1 is considered to be constitutively expressed, while
COX-2 is highly inducible by various factors and is asso-
ciated with tumorigenesis by enhancing angiogenesis [1,2],* Correspondence: dzj0911@126.com; kanghf73@yahoo.com.cn;
Wangxijing@21cn.com
†Equal contributors
Department of Oncology, the Second Affiliated Hospital, Medical School of
Xi’an Jiaotong University, Xi’an 710004, China
© 2012 Dai et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsuppressing apoptosis [3], and promoting invasiveness as
well as metastases [4].
COX-2 promotes carcinogenesis, tumor proliferation,
angiogenesis, prevention of apoptosis, and immunosup-
pression [5]. COX-2 over-expression has been associated
with tumor behavior and with prognosis in several can-
cers [6]. The selective inhibition of COX-2 activity in
several animal models has been associated with a de-
crease of new blood vessel production in tumors, a de-
crease in new vessel formation, and an increase in tumor
cell apoptosis [7]. Celecoxib is a paradigmatic selective
inhibitor of COX-2. This anti-inflammatory drug has
potent anti-tumor activity in a wide variety of human. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[8-10].
The over-expression of COX-2 is associated with
carcinogenesis, invasiveness, and with the metastasis of
malignant tumors [11,12]. The roles of celecoxib in pre-
venting and treating tumors have been attracting broad
attention in recent years because of its selective and spe-
cific inhibition of COX-2 activity [13-16]. In this study,
the inhibitory effect of celecoxib on the proliferation of
the human breast carcinoma cell line MCF-7 was inves-
tigated in vitro and the breast cancer was chemically
induced in vivo.Materials and methods
Reagents
MCF-7 cell was purchased from the Shanghai Institute of
Cell Biology at the Chinese Academy of Sciences (Shanghai,
P.R.China). RPMI1640 medium (Gibco, USA); Fetal bovine
serum(Gibco, USA); 7,12-dimethylbenanthracene (DMBA),
Dimethyl sulfoxide (DMSO), Propidiumiodide(PI) and 3-
(4,5- dimethylthiazol-2-yl) -2,5- diphenytetrazolium brom-
ide (MTT) were purchased from Sigma Chemical (St.
Louis, MO); Trizol (Invitrogen, USA);Celecoxib(Pfizer
Pharmaceuticals Ltd, USA); Prostaglandin E2(PGE2) ELISA
kit(Jingmei Biotech Co.,Ltd, China). Rats(Sprague–Dawley
rats, female, age 45±5 days, weighting 110±10g) were pur-
chased from the Experiment Animal Center, Medical
School of Xi'an Jiaotong University, Xi’an, China (Animal
Certificate Number: No.08-005 of Shanxi medical animal
test centre).Cell culture and cell proliferation assay
Cells were cultured in RPMI-1640 medium(Gibco, USA)
supplemented with 10% fetal bovine serum (Gibco, USA),
1 ×105 U/L penicillin and 100 mg/L streptomycin in a hu-
midified atmosphere with 5% CO2 incubator at 37°C. The
cells were subcultured until reaching logarithmic growth
phase.
MTT assay was used to determine the effect of Cele-
coxib on the proliferation of MCF-7 cells. MCF-7 cells
were seeded at a concentration of 5×103 cell /well in 96-
well plate, and grown at 37°C, 5% CO2 incubator until
adherence. After an overnight incubation in starvation
medium containing 0.5% FBS, the cells on the culture
plate were divided into groups on the basis of parallel
lines, each group had four wells in one line for each group.
At the end of the treatment, 20 μl MTT (5 mg/ml) was
added and the cells were incubated for another 4 hours.
200 μl of DMSO was added to each well after removing
the supernatant. After shaking the plate for 10 mins. in
the shaking board, cell viability was obtained by measuring
the absorbance at 490 nm wavelength using Enzyme-
labeling instrument (Bio-Tek ELX800, USA), this assaywas done triplicate. The inhibition rate was calculated
using the following formula [17]:
Inhibition rate(%) =[1-(average absorbance of experi-
mental group/average absorbance of blank control
group)] × 100%.
Real-time quantitative RT-polymerase chain reaction
assay for COX-2 expression
MCF-7 cells were seeded in 6-well plates and treated with
concentration gradient Celecoxib (0, 10,20,40 μmol/L) se-
parately for 0-96 h. As previously described [18], cells col-
lected at specified time were used to extract total RNA
using the Trizol reagent following the manufacturer’s ins-
tructions. RNA was reverse-transcribed into cDNA using
a Primescript™ RT reagent kit according to the manu-
facturer’s instructions. Real-time quantitative polymerase
chain reaction (PCR) was carried out with the SYBR Green
fluorescent dye method, and a Rotor Gene 3000 real-time
PCR apparatus. COX-2 primer sequence (Invitrogen CO):
50- ATCCTTGCTGTTCCCACCA-30 (sense) and 50-CTT
TGACACCCAAGGGAGT-30 (anti-sense). β-actin, its pri-
mer sequence was 50-GTTGCGTTACACCCTTTCTTG-30
(sense), 50-TGCTGTCACCTTCACC GTTC-30 (anti-
sense). β-actin was used as an internal control to evaluate
the relative expressions of COX-2. The PCR conditions
were as follows: a pre-denaturing at 95°C for 2 min, fol-
lowed by 45 cycles of denaturation at 95°C for 10 s,
annealing/extension at 60°C for 20 s. The amplification
specificity was checked by melting curve analysis. The
PCR products were visualized by gel electrophoresis to
confirm the presence of a single product with a correct
size. The 2-ΔΔCT method was used to calculate the relative
abundance of target gene expression generated by Rotor-
Gene Real-Time Analysis Software 6.1.81. For each cDNA,
the target gene mRNA level was normalized to β -actin
mRNA level. The experiments were performed for three
times.
Determination of PGE2 synthesis
As previously described [19], MCF-7 Cells were grown in
12-well plates overnight. 30 min before harvesting of cul-
ture media, the culture media of the cells were changed to
new media, and then these culture media were centrifuged
to remove cell debris. Cell-free culture media were col-
lected at indicated times and PGE2 levels were determined
by competitive enzyme-linked immunosorbent assay
(ELISA) as described by the kit manufacturer (Cayman
Chemical, Ann Arbor, MI, USA) using an ELISA reader
(μQuant; Biotek Instruments, Inc, Winooski, VT, USA).
Cell cycle analysis by FCM
MCF-7 cells were incubated at 5 × 105 cells/well in
6-well plates, treated with a homologous drug for 48 h.
The detached and attached cells were harvested and
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fixation, cells were washed with PBS, resuspended in
1 mL PBS containing 1 mg/mL RNase (Sigma) and
50 μg/mL PI (Sigma), and incubated at 37°C for 30
min in the dark. Samples of 10 000 cells were then
analyzed for DNA content by FACScan flow cytome-
try (Beckman, USA), and cell cycle phase distributions
were analyzed with the CellQuest acquisition software
(BD Biosciences).Antitumor activity in vivo
All the animals were maintained under standard envi-
ronmental conditions and provided with food and water
ad libitum. All the animals were fed with a normal pellet
diet one week prior to the experimentation.
Female Sprague–Dawley rats were gavaged with 60
mg of DMBA/kg body weight, which was sufficient to
cause 100% tumor incidence in the rats over the
course of the study, as described by Whitsett et al.
[20]. The DMBA was dissolved in olive oil at a stock so-
lution of 30 mg/ml.
After modeling, 90 rats were randomly divided into
three groups, namely, the control group(normal diet after
modeling), which was considered as the negative control,
the positive control (tamoxifen) group (4 mg/kg of tam-
oxifen was put in drinking water), and celecoxib group
(solved in the oleum maydis, 1000 mg/kg of celecoxib was
put in forage). The breasts of the rats were assessed twice
a week, when palpable breast neoplasm appeared. The
number of breast neoplasms and their changes in size
were recorded.
After 120 days, the experiment was stopped. A vaginal
smear examination was performed to confirm that the rats
were in the dioestrus period. The rats were anesthetized
by an intraperitoneal injection of 5% urethane. Then,
every mammary gland with surrounding skin and hypo-
dermia were dissected.The mammary glands were cut half
open to observe the tumor shape and to count the num-
ber of tumors. The size of the tumors was measured using
a 1mm precision sliding caliper. The tumor incidence rate
of each group was calculated. The tumor volumes was
calculated according to the following equation: length ×
weight × height × π/6 [21]. If one rat had many tumors,
the volume of this rat was the sum of all its tumors.
The specimens were fixed in 10% neutral formalin,
embedded in paraffin and stained with hematoxylin-
eosin for the histological examination. The diagnosis of
rat breast cancer was performed according to the diag-
nostic code of experimental rat breast cancer [22].Statistical analysis
All values were expressed as the mean ± standard devia-
tions (SD). Statistical analysis was performed with one-way analysis of variance (ANOVA) and student t test
using the statistical software SPSS 13.0. P<0.05 was con-
sidered as statistically significant.
Results and discussions
Celecoxib inhibited the proliferation of breast cancer cells
in vitro
The anti-proliferative effect of celecoxib on two breast can-
cer cell lines, MCF-7 cells (ER –positive) and MDA-MB-
231 (ER-negative), were examined using MTT assays. Cells
were treated with medium and different doses of celecoxib,
and the inhibition rate was evaluated after 0 h to 96 h. Cel-
ecoxib in the high dose and medium dose groups could
significantly inhibit the proliferation of both MCF-7 cells
and MDA-MB-231 cells. As shown in Figure 1, the inhibi-
tory rates of celecoxib on cell growth were (62.6±4.5)%,
(67.5±4.8)%, (78.7±6.3)% in MCF-7 cells, and 53.5±3.7)%,
(62.3±4.5)%, (70.9±7.1)% in MDA-MB-231 cells, when the
cells were treated with different doses of celecoxib for 96
hours. Thus, Celecoxib inhibited breast cancer cell proli-
feration in a dose- and time-dependent manner.
Celecoxib is known to induce apoptosis [23], but its
effect on proliferative is not conclusive. For example,
some researches reported that celecoxib did not affect
tumor cell proliferation in primary adenocarcinomas and
ductal carcinoma in situ of the breast in vivo [24,25].
However, celecoxib could prevent the development of
breast cancer with ER-negative and HER-2-positive sta-
tus [26]. These results indicate that the effect on prolifera-
tive of celecoxib is related with tumor`s molecular
phenotype possibly. In this study, we choose a ER –positive
breast cancer cell line (MCF-7) and a ER –negative breast
cancer cell line (MDA-MB-231), and found celecoxib
could significantly inhibit the proliferation of both MCF-7
cells and MDA-MB-231 cells in a dose- and time-
dependent manner.
COX-2 mRNA expression detected by real-time qPCR
Real-time qPCR assay was used for COX-2 mRNA expres-
sion. It revealed that COX-2 mRNA was highly expressed
in normal breast cancer cells. What’s more, as celecoxib
concentration increased, the mRNA expression of COX-2
gradually decreased. As shown in Figure 2, the amount of
COX-2 mRNA in both MCF-7 cells and MDA-MB-231
cells after celecoxib treatment were significantly decreased
in a dose-dependent manner.
It was previously reported that COX-2 is expressed in
most human cancers including those of the breast, and
administration of selective COX-2 inhibitors in humans
may reduce the risk of cancer development [27]. Our
date indicated that cell viability was gradually declined
as celecoxib concentration increased. As can been seen,
the lowest COX-2 mRNA was in 40 μmol/L group. There-
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Figure 1 Growth inhibiting effects of Celecoxib in MCF-7 cells (A) and MDA-MB-231 cells (B). Cell viability was determined by MTT
method. This assay was performed in triplicate. Dose- and time-dependent inhibition of cell growth could be observed after 96 h (P<0.05, ANOVA
analysis). *P<0.05, ** P<0.01 vs. 24 h; #P<0.05, ## P<0.01 vs.10 μmol/L celecoxib.
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cacy of celecoxib against breast cancer growth.
Effects of celecoxib on the PGE2 level of MCF-7 cells by
ELISA
Prostaglandin E2 (PGE2) is an important mediator in
tumor-promoting inflammation [28]. The major mechan-
ism of COX-2 in stimulating tumorigenesis is its product,
PGE2. PGE2 promotes tumor cell proliferation, induces
VEGF up-regulating, and inhibits tumor cell apoptosis as
well as immune function [29]. Tari et al. [30] reported that
COX-2 induced PGE2 to stimulate the activities of protein
kinases A and C and induced tamoxifen resistance in ER
alpha-positive breast cancer cells selectively. However, the
COX-2 selective inhibitor celecoxib can inhibit tumori-
genesis and tumor development through these ways.
In this study, the PGE2 level of MCF-7 cells was deter-
mined with ELISA analysis. As shown in Figure 3, the
PGE2 level of MCF-7 cells in the control group and in the
10 μmol/L to 40 μmol/L celecoxib groups were (75.32
±8.73), (58.15±6.56), (42.84±6.12) and (28.65±4.33) pg/mL,
respectively. PGE2 levels in the celecoxib therapy groups
were significantly lower than that in the control group.Furthermore, the PGE2 level gradually decreased in a
dose-dependent manner (P <0.01).Effects of celecoxib on the cell cycle distribution by flow
cytometry
Celecoxib may exert an inhibitory effect on the en-
hanced radiation-induced G2/M arrest in the COX-2-
overexpressing cells. This effect may allow the arrested
cells to enter mitosis and die after radiation [31]. It has
been found that a low dose of celecoxib (5 μM to 10 μM)
could induce G2/M arrest, followed by the induction of
apoptosis in the transformed cells but not in the normal
cells. Growth inhibition was related to the COX-2 function
with 90% to 95% reduction in PGE2 production [32]. How-
ever, Liu et al. [33] holds a different opinion that celecoxib
can induce apoptosis and cell-cycle arrest at the G0/G1
checkpoint in the nasopharyngeal carcinoma cell lines,
which is associated with a significantly reduced STAT3
phosphorylation.
In the present study, the effects of celecoxib on cell
cycles were analyzed using flow cytometry. The percen-
































Figure 2 Effect of Celecoxib on expression of COX-2 mRNA of MCF-7 cells by real-time qPCR analysis. A: Control group; B: 10 μmol/L
Celecoxib; C: 20 μmol/L Celecoxib; D: 40 μmol/L Celecoxib. The expression of COX-2 mRNA in MCF-7 cells were determined by real-time qPCR
after treated with 0-40μmol/L celecoxib for 48 h. This assay was done triplicate. Values represent means ± standard deviations and were
determined using the Student’s t-test. *P<0.05,** P<0.01 vs. control.
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phase. These results suggest that celecoxib can induce cell
cycle arrest at the G0/G1 phase in MCF-7 cells (Figure 4).
Besides, the cells at the G2/M phase significantly decreased























Figure 3 Effects of celecoxib on the PGE2 level of MCF-7 cells by ELIS
D: 40 μmol/L celecoxib. PGE2 levels of MCF-7 cells were determined by EL
done triplicate. Values represent means ± standard deviations and were deAnti-tumor effects of celecoxib on DMBA-induced
breast cancer
Celecoxib has a striking chemopreventive activity. It can
inhibit preneoplastic lesions during hepatocarcinogene-
sis in vivo, which suggests that celecoxib effects are
mediated by PGE2-independent mechanisms [34]. A low**
**
C D
A. A: control group; B: 10 μmol/L celecoxib; C: 20 μmol/L celecoxib;
ISA after treated with 0-40 μmol/L celecoxib for 48 h. This assay was













































Figure 5 Anti-tumor effects of celecoxib on DMBA induced
breast cancer. A. the incidence rate of the different groups; B. the
tumor latency period of the different groups; C. the average tumor
volumes of the different groups. Values represent means ± standard
deviations and were determined using the Student’s t-test. *P < 0.05











Figure 4 Effects of celecoxib on the cell cycle of MCF-7 cells by flow cytometry. A: control group; B: 10 μmol/L celecoxib; C: 20 μmol/L
celecoxib; D: 40 μmol/L celecoxib. The cell cycle distributions in MCF-7 cells were determined by PI staining and flow cytometric analysis after
treated with 0-40 μmol/L celecoxib for 48 h. Results presented were representative of three independent experiments.
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inhibition of Tca8113 cells and its xenograft in Balb/c
nude mice [35]. It is reported by Nakatsug et al. [21] that
400 ppm of nimesulide could degrade tumor incidence
rate, volume and multisitus rate. This study found that
celecoxib could inhibit rat carcinogenesis and cancer de-
velopment. With a dosage of 1000 ppm, celecoxib de-
creased the incidence rate, average tumor number and
tumor volume with statistical significance (P<0.05), com-
pared with that of tumor control group. As in vitro, cele-
coxib inhibited MCF-7 cell proliferation in a dose- and
time-dependent manner, while in vivo, celecoxib could
inhibit rat carcinogenesis and cancer development in a
dose-dependent manner. Abou Issa et al. [9] observed
the preventive effect of celecoxib on 7,12-dimethylben
anthracene (DMBA)-induced rat breast cancer. When trea-
ted with 250 ppm, 500 ppm, 1000 ppm and 1500 ppm ce-
lecoxib, the incidence rate was 80%, 50%, 45% and 25%
respectively, compared with that of 100% incidence rate in
control group (P<0.001).
In the present study, celecoxib was found to be cap-
able of inhibiting rat carcinogenesis and cancer develop-
ment. The tumor incidence rate of each group was
85.71% (24/28) in the control group, 50.00% (14/28) in
the celecoxib group, and 48.15% (13/27) in the tamoxi-
fen group. As shown in Figure 5, the tumor latency
period of the celecoxib group was significantly longer
than that of the control group (P < 0.05). In addition, no
significant difference was found between the celecoxib
and tamoxifen groups (P > 0.05).
The average tumor numbers of each group were as fol-
lows: 3.50±1.62(1-7) pieces in the control group; 1.77±0.73
(1-3)pieces in the tamoxifen group; and 1.71±0.61(1-2)
pieces in the celecoxib group. The average tumor numbers
of the celecoxib and tamoxifen groups were less than that
A B
C D
Figure 6 Breast sections of the different groups. A. Infiltrating ductal cancer in control group; B. Atypical hyperplasia in control group;
C. Infiltrating ductal cancer in celecoxib group; D. Hyperplasia in celecoxib group (HE×200).
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was found between the two treatment groups (P > 0.05).
The average tumor volumes of each group were
6.42±3.96cm3 in the control group, 1.78±0.71cm3 in
the tamoxifen group, and 2.05±1.04cm3 in the cele-
coxib group. No significant difference was found
between the tumor volumes of the celecoxib and
tamoxifen groups (P > 0.05). The tumor volumes of
the two treatment groups decreased significantly
compared with the tumor control groups (P < 0.05).
Histopathological observation
The tissues of the control group presented an infiltrating
ductal carcinoma, showing cancer nest, obvious nuclear
atypia and nuclear division. A few gland-like structures
and stroma were also observed (Figure 6A). The medul-
lary carcinoma was composed of cancer cells and had
ductless glands. The specimens without tumorigenesis
showed different degrees of lobuli mammae hyperplasia
and glandular epithelium atypical hyperplasia. The slight
degree of hyperplasia showed an expanded or increased
intralobulus and interlobulus fibrous tissue and gland al-
veolus. However, acinous cells were still in the monolayer.
The atypical hyperplasia showed acinous cells that were
arranged disorderly and in a multilayer, an increased kar-
yoplasmic ratio, and changed nuclear atypia (Figure 6B).
In the experimental groups, the infitrating ductal car-
cinoma had more gland-like structures and stroma
wherein the cells were dispersed. A few nuclear atypia
and nuclear division were also observed (Figure 6C).
The specimens that did not cancerate showed no or a
slight degree of glandular epithelium hyperplasia, increasedintralobulus and interlobulus fibrous tissue, and lesser
gland alveolus and ducts (Figure 6D).
Conclusions
In conclusion, celecoxib inhibited the proliferation of
breast cancer cell lines in vitro. Furthermore, the inhi-
bitory effect of celecoxib on the proliferation of breast
cancer cells in vitro was observed in a dose- and time-
dependent manner. The cell cycle was arrested at G0/
G1, and the rate of cells in the S phase was obviously
decreased. In addition, celecoxib could prevent the oc-
currence of rat breast cancer in vivo. Therefore, cele-
coxib exhibits an antitumor activity and seems to be
effective in anti-tumor therapy. However, further studies
are needed to clarify the detailed mechanism involved in
the antitumor effects of celecoxib.
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